Should studies of diabetes treatment stratification correct for baseline HbA1c?

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Jones, Angus G ^a   Lonergan, Mike ^b   Henley, William E ^c   Pearson, Ewan R ^b   Hattersley, Andrew T ^a   Shields, Beverley M ^a  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ERROR; PREDICTION; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 2;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE;

EID: 84962891375     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152428     Document Type: Article

References (25)

1. Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an openlabel randomised trial. Lancet. 2010;375(9733):2234-43. doi: 10.1016/S0140-6736 (10) 60406-0 PMID: 20609969
2. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes care. 2006;29(9):2137-9. PMID: 16936168
3. De Fronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabetic medicine: a journal of the British Diabetic Association. 2010;27(3):309-17.
4. Giugliano D, Maiorino M, Bellastella G, Chiodini P, Esposito K. Relationship of baseline HbA1c, HbA1c change and HbA1c target of <7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2011;65(5):602-12. doi: 10.1111/j.1742-1241.2010.02619.x PMID: 21489084
5. Gale EA, Beattie SD, Hu J, Koivisto V, Tan MH. Recruitment to a clinical trial improves glycemic control in patients with diabetes. Diabetes care. 2007;30(12):2989-92. PMID: 17804681
6. t'Hart LM, Fritsche A, Nijpels G, van Leeuwen N, Donnelly LA, Dekker JM, et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes. 2013;62(9):3275-81. doi: 10.2337/db13-0227 PMID: 23674605
7. Thong KY, McDonald TJ, Hattersley AT, Blann AD, Ramtoola S, Duncan C, et al. The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study. Diabetic medicine 2013;31(4):403-11 doi: 10.1111/dme. 12367 PMID: 24246138
8. Yanez ND 3rd, Kronmal RA, Shemanski LR. The effects of measurement error in response variables and tests of association of explanatory variables in change models. Stat Med. 1998;17(22):2597-606. PMID: 9839350
9. Glymour MM, Weuve J, Berkman LF, Kawachi I, Robins JM. When is baseline adjustment useful in analyses of change? An example with education and cognitive change. Am J Epidemiol. 2005;162(3):267-78. PMID: 15987729
10. McArdle PF, Whitcomb BW. Improper adjustment for baseline in genetic association studies of change in phenotype. Human heredity. 2009;67(3):176-82. doi: 10.1159/000181156 PMID: 19077436
11. Yanez ND3rd, Kronmal RA, Shemanski LR, Psaty BM, Cardiovascular Health S. A regression model for longitudinal change in the presence of measurement error. Annals of epidemiology. 2002;12(1):34-8. PMID: 11750238
12. Harrison L, Dunn DT, Green H, Copas AJ. Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data. Stat Med. 2009;28(26):3260-75. doi: 10.1002/sim.3725 PMID: 19768690
13. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. International journal of epidemiology. 2005;34(1):215-20. PMID: 15333621
14. Hopewell JC, Parish S, Offer A, Link E, Clarke R, Lathrop M, et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. European heart journal. 2013;34(13):982-92. doi: 10.1093/eurheartj/ehs344 PMID: 23100282
15. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabetic medicine: a journal of the British Diabetic Association. 2002;19(4):279-84.
16. Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulfonylureas in Type 2 diabetes. Diabetic medicine: a journal of the British Diabetic Association. 2006;23(2):128-33.
17. Jones AG, McDonald TJ, Shields BM, Hill AV, Hyde CJ, Knight BA, et al. Markers of beta-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes care. 2015;39(2):250-7 doi: 10.2337/dc15-0258 PMID: 26242184
18. Kraha A, Turner H, Nimon K, Zientek LR, Henson RK. Tools to support interpreting multiple regression in the face of multicollinearity. Frontiers in psychology. 2012;3:44. doi: 10.3389/fpsyg.2012.00044 PMID: 22457655
19. Senn S. Statistical Issues in Drug Development. Second Edition ed: Wiley; 2007. p. 95-112.
20. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nature reviews Drug discovery. 2007;6(4):287-93. PMID: 17380152
21. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations. The New England journal of medicine. 2006;355(5):467-77. PMID: 16885550
22. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemiaand response to treatment in diabetes. Lancet. 2003;362(9392):1275-81. PMID: 14575972
23. Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 1: background, methodology, and clinical adoption of pharmacogenetics. Oncologist. 2011;16(6):811-9. doi: 10.1634/theoncologist.2010-0258 PMID: 21632456
24. Abstracts 889, 893, 894, 895, 896,. Diabetologia. 2013;56 ([suppl 1]).
25. Senn S. Change from baseline and analysis of covariance revisited. Stat Med. 2006;25(24):4334-44. PMID: 16921578